Advances in Hematology / 2010 / Article / Tab 1

Review Article

Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Table 1

Studies on high-dose therapy and autologous stem cell transplantation in PTCL as second-line therapy.

Retrospective data
AuthorYear AgeHistologies (WHO)IPIHigh-dose regimenStatus at TxDFS/EFS/ PFS/RFSOSFollowup (months)Comment

Vose et al. [22]19901733No data No dataDiverseCR 42%
PR 26%
28% (2 y)35% (2 y)28

Fanin et al. [23]19996425ALCL 100%aaIPI
0/1   48%
2/3   22%
Unknown 30%
DiverseCR 47%56% (5 y)70% (5 y)4334/64 transplanted 2.line

Rodríguez et al. [24]20012943No data 0/1   31%
2   41%
3   21%
4/5   7%
DiverseCR 38%
PR 48%
32% (3 y)39% (3 y)43

Blystad et al. [25]20014042PTCLu 50%
ALCL 35%
Other 15%
aaIPI
0/1   42%
2/3   45%
Unknown 13%
DiverseCR 70%
PR 30%
56% (3 y)58% (3 y)2523/40 transplanted 2.line

Song et al. [26]20023646PTCLu 56%
ALCL 25%
NK/T 11%
Other 8%
No dataMel/EtoCR 42%
PR 50%
37% (3 y)48% (3 y)42

Rodríguez et al. [27]200311541PTCLu 63%
ALCL 22%
NK/T 15%
aaIP
0/1   40%
2/3   60%
DiverseCR 56%
PR 38%
60% (5 y)
49% (5 y)
56% (5 y)
45% (5 y)
3778/115 transplanted 2.line

Schetelig et al. [28]20032951AITL 100%aaIPI
0/1   21%
2/3   79%
DiverseNo data37% (5 y)
39% (5 y)
60% (5 y)
44% (5 y)
6015/29 transplanted 2.line

Zamkoff et al. [29]20041652 100%aaIPI
0/1   67%
2/3   33%
DiverseCR 60%
PR 40%
12 w (median)72 w (median)No data

Jantunen et al. [30]20043746PTCLu 38%
ALCL 38%
EATL 14%
Other 11%
0/1   46%
2   22%
3   19%
4/5   14%
Unknown 3%
BEAC/BEAMCR/PR 87%44% (5 y)
28% (5 y)
54% (5 y)
45% (5 y)
2419/37 transplanted 2.line TRM 16%

Jagasia et al. [31]20042839ALCL 57%
PTCLu 21%
AITL 11%
NK/T 11%
aaIPI
0/1   29%
2/3   50%
Unknown 21%
Cy/Eto/TBI or CBVCR 39%
PR 46%
50% (3 y)69% (3 y)447/28 underwent alloSCT

Kewalramani et al. [32]20062448PTCLu 58%
ALCL 17%
AITL 17%
Other 8%
aaIPI
0/1   46%
2/3   54%
DiverseCR 63%
PR 37%
24% (5 y)33% (5 y)72

Kim et al. [33]20074044PTCLu 50%
NK/T 25%
ALCL 13%
Other 13%
aaIPI
0/1   45%
2/3   53%
Unknown 3%
DiverseCR 28%
PR 52%
No data11.5 m (median)1629/40 transplanted 2.line

Smith et al. [34]20073244ALCL 66%
PTCLu 34%
aaIPI (at Tx)
0/1   72%
2/3   28%
BECNo data18% (5 y)34% (5 y)3026/32 transplanted 2.line

Chen et al. [35]20085345ALCL 34%
PTCLu 30%
AITL 17%
Other 19%
No dataDiverseCR/PR 89%25% (5 y)
9% (5 y)
48% (5 y)
37% (5 y)
6038/53 transplanted 2.line

Lee et al. [36]20084742 NK/T 100%aaIPI
0/1   82%
2/3   18%
CVB/BEAM/ MCEC (72%)CR 58%No dataNo data11733/47 transplanted 2.line

Yang et al. [37]20096444PTCLu 100%aaIPI
0/1   56%
2/3   44%
BEAM/CVB (70%)CR 33%
PR 58%
44% (3 y)
33% (3 y)
53% (3 y)
46% (3 y)
3036/64 transplanted 2.line

Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group
classified according to the Working Formulation
for the subgroup of patients transplanted 2.line.